Although in vitro detection of cytolytic activity does not always correlate with in vivo tumour rejection, the potential of the C595scFv-Fc-IL2 fusion protein to activate immunocompetent resting NK and preactivated T cells after binding to MUC1-positive tumour cells is clearly demonstrated. This evidence concerns the gene MUC1 and neoplasm.